JP Morgan Chase
RIGL icon

JP Morgan Chase’s Rigel Pharmaceuticals RIGL Stock Holding History

JP Morgan Chase’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
41,084
+4,070
+11% +$137K ﹤0.01% 4578
2025
Q4 		$1.59M Buy
37,014
+2,054
+6% +$77.4K ﹤0.01% 4272
2025
Q3 		$990K Buy
34,960
+25,013
+251% +$748K ﹤0.01% 4608
2025
Q2 		$186K Sell
9,947
-45,480
-82% -$862K ﹤0.01% 5267
2025
Q1 		$997K Sell
55,427
-125,065
-69% -$2.54M ﹤0.01% 4346
2024
Q4 		$3.04M Buy
180,492
+154,254
+588% +$2.96M ﹤0.01% 3828
2024
Q3 		$425K Buy
26,238
+8,140
+45% +$95.7K ﹤0.01% 5006
2024
Q2 		$149K Buy
18,098
+7,827
+76% +$81.9K ﹤0.01% 5312
2024
Q1 		$152K Sell
10,271
-2,551
-20% -$34.4K ﹤0.01% 5485
2023
Q4 		$186K Sell
12,822
-8,583
-40% -$87.8K ﹤0.01% 5423
2023
Q3 		$231K Sell
21,405
-5,699
-21% -$68.6K ﹤0.01% 4977
2023
Q2 		$350K Sell
27,104
-25,147
-48% -$340K ﹤0.01% 4716
2023
Q1 		$690K Buy
52,251
+35,080
+204% +$557K ﹤0.01% 4296
2022
Q4 		$258K Buy
17,171
+4,269
+33% +$39.1K ﹤0.01% 4907
2022
Q3 		$152K Buy
12,902
+3,449
+36% +$46.6K ﹤0.01% 5079
2022
Q2 		$107K Sell
9,453
-54
-0.6% -$1.08K ﹤0.01% 5374
2022
Q1 		$284K Buy
9,507
+1,937
+26% +$52.4K ﹤0.01% 4995
2021
Q4 		$201K Sell
7,570
-52
-0.7% -$1.57K ﹤0.01% 5351
2021
Q3 		$276K Buy
7,622
+184
+2% +$7.24K ﹤0.01% 5063
2021
Q2 		$323K Buy
7,438
+1,031
+16% +$38.9K ﹤0.01% 4968
2021
Q1 		$219K Sell
6,407
-51,692
-89% -$2.05M ﹤0.01% 5114
2020
Q4 		$2.03M Buy
58,099
+51,764
+817% +$1.5M ﹤0.01% 3467
2020
Q3 		$145K Sell
6,335
-34,079
-84% -$837K ﹤0.01% 4527
2020
Q2 		$740K Sell
40,414
-23,025
-36% -$414K ﹤0.01% 3674
2020
Q1 		$990K Buy
63,439
+44,876
+242% +$955K ﹤0.01% 3408
2019
Q4 		$397K Buy
18,563
+13,048
+237% +$269K ﹤0.01% 4358
2019
Q3 		$103K Sell
5,515
-53,621
-91% -$1.11M ﹤0.01% 4895
2019
Q2 		$1.45M Buy
59,136
+55,040
+1,344% +$1.24M ﹤0.01% 3608
2019
Q1 		$105K Sell
4,096
-193
-4% -$4.41K ﹤0.01% 4871
2018
Q4 		$99K Sell
4,289
-9,254
-68% -$261K ﹤0.01% 4856
2018
Q3 		$435K Sell
13,543
-127,300
-90% -$3.82M ﹤0.01% 4342
2018
Q2 		$3.99M Sell
140,843
-61,319
-30% -$2.18M ﹤0.01% 2859
2018
Q1 		$7.16M Buy
202,162
+65,286
+48% +$2.61M ﹤0.01% 2283
2017
Q4 		$5.31M Sell
136,876
-2,989
-2% -$114K ﹤0.01% 2638
2017
Q3 		$3.25M Sell
139,865
-6,290
-4% -$153K ﹤0.01% 2873
2017
Q2 		$3.99M Buy
146,155
+1,184
+0.8% +$32.4K ﹤0.01% 2625
2017
Q1 		$4.8M Sell
144,971
-33,378
-19% -$851K ﹤0.01% 2458
2016
Q4 		$4.25M Sell
178,349
-37,876
-18% -$1.08M ﹤0.01% 2586
2016
Q3 		$7.94M Buy
216,225
+57,352
+36% +$1.64M ﹤0.01% 1926
2016
Q2 		$3.54M Buy
+158,873
New +$3.95M ﹤0.01% 2503
2014
Q1 		– Sell
-1,102
Closed -$31K – 3878
2013
Q4 		$31K Sell
1,102
-8,023
-88% -$236K ﹤0.01% 3995
2013
Q3 		$327K Buy
9,125
+2,753
+43% +$100K ﹤0.01% 3834
2013
Q2 		$213K Buy
+6,372
New +$289K ﹤0.01% 3961

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's RIGL Position: Q1 2026 in Review

JP Morgan Chase increased its Rigel Pharmaceuticals (RIGL) stake by 11% in Q1 2026, buying an estimated $137K and bringing the position to 41,084 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #4578.

JP Morgan Chase first reported a position in RIGL in Q2 2013 and has held it in 43 quarters since. The position peaked at $7.94M in Q3 2016. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • JP Morgan Chase held 41,084 shares of Rigel Pharmaceuticals worth $1.06M as of Q1 2026.
  • JP Morgan Chase bought 4,070 Rigel Pharmaceuticals shares in Q1 2026, an estimated $137K.
  • Rigel Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4578 holding.
  • JP Morgan Chase first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • JP Morgan Chase's Rigel Pharmaceuticals position peaked at $7.94M in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.